Skip to main content
Top

17-06-2024 | Glioblastoma | Review Article

Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms

Authors: Tong Xiao, Hao Zheng, Kaiyang Zu, Youjia Yue, Ying Wang

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Tumor-Treating Fields (TTFields) use intermediate-frequency and low-intensity electric fields to inhibit tumor cells. However, their mechanisms are still not well understood. This article reviews their key antitumor mechanisms at the cellular and molecular levels, including inhibition of proliferation, induction of death, disturbance of migration, and activation of the immune system. The multifaceted biological effects in combination with other cancer treatments are also summarized. The deep insight into their mechanism will help develop more potential antitumor treatments.
Literature
3.
go back to reference Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (stellar): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702–9. https://doi.org/10.1016/S1470-2045(19)30532-7.CrossRefPubMed Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (stellar): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702–9. https://​doi.​org/​10.​1016/​S1470-2045(19)30532-7.CrossRefPubMed
5.
go back to reference Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (lunar): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002–17. https://doi.org/10.1016/S1470-2045(23)00344-3.CrossRefPubMed Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (lunar): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002–17. https://​doi.​org/​10.​1016/​S1470-2045(23)00344-3.CrossRefPubMed
20.
35.
go back to reference Lee WS, Kim EH. Combination therapy of doxorubicin with TTFields and radiation: newer approaches to combat lung cancer. Am J Cancer Res. 2022;12(6):2673–85.PubMedPubMedCentral Lee WS, Kim EH. Combination therapy of doxorubicin with TTFields and radiation: newer approaches to combat lung cancer. Am J Cancer Res. 2022;12(6):2673–85.PubMedPubMedCentral
78.
go back to reference Kim JS, Cho JM, Kim H, Jeong YK, Kim JK, Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res. 2021;11(8):3935–45.PubMedPubMedCentral Kim JS, Cho JM, Kim H, Jeong YK, Kim JK, Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res. 2021;11(8):3935–45.PubMedPubMedCentral
90.
go back to reference Jo Y, Han YI, Lee E, Seo J, Oh G, Sung H, et al. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3. Am J Cancer Res. 2022;12(3):1423–32.PubMedPubMedCentral Jo Y, Han YI, Lee E, Seo J, Oh G, Sung H, et al. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3. Am J Cancer Res. 2022;12(3):1423–32.PubMedPubMedCentral
91.
go back to reference Lee WS, Seo SJ, Chung HK, Park JW, Kim JK, Kim EH. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy. Am J Cancer Res. 2021;11(9):4582–94.PubMedPubMedCentral Lee WS, Seo SJ, Chung HK, Park JW, Kim JK, Kim EH. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy. Am J Cancer Res. 2021;11(9):4582–94.PubMedPubMedCentral
Metadata
Title
Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms
Authors
Tong Xiao
Hao Zheng
Kaiyang Zu
Youjia Yue
Ying Wang
Publication date
17-06-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03551-z

2024 ASCO Annual Meeting Coverage

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare